Shalby Ltd Forensic Report - SOIC x StockScans Report

as of Aug 2026

Shalby’s standalone hospital business remains profitable, and the audit record is clean: seven consecutive years of unqualified opinions on both standalone and consolidated statements, though the FY2025-26 standalone auditor's report identifies multiple Key Audit Matters. The consolidated picture is different. Subsidiary losses absorbed 66.5% of standalone profit in FY2025-26, net debt more than tripled to ₹446.22 crore, and reported profit is not backed by operating cash flow. The risk sits in the MedTech and PK Healthcare subsidiaries, where large guarantees, repeated impairments, and a widening loss tail have not yet been resolved.

Key findings

  1. Subsidiary losses absorb two-thirds of standalone profit Major - Consolidated profit after tax was ₹37.51 crore against standalone profit of ₹112 crore in FY2025-26, meaning 66.5% of standalone profit was absorbed at subsidiaries. Thirteen subsidiaries audited by the parent’s auditor had total revenues of ₹419.49 crore and a combined net loss of ₹71.65 crore for the year ended March 31, 2026. The subsidiary count has grown from 8 in March 2022 to 14 in March 2026, while the FY2024-25 governance report lists over 200 Shalby Medtech entities across five regions.
  2. Net debt triples while the “debt-free” claim persists Major - Consolidated net debt rose from ₹279.00 crore in FY2024-25 to ₹446.22 crore in FY2025-26, with a net debt-to-equity ratio of 0.44 times. Management had claimed in FY2022-23 that the company was “debt-free” while reporting an outstanding loan balance of ₹141.7 crore, and made the same claim in FY2020-21 with ₹44.03 crore outstanding. ICRA reaffirmed the long-term rating at ICRA A+ but revised the outlook to Negative from Stable.
  3. Large guarantees back loss-making subsidiaries Major - Shalby issued a corporate guarantee of up to ₹716 crore to HDFC Bank for credit facilities to PK Healthcare on 7th November 2025. Shareholder authorisation under Section 186 for loans, guarantees and investments was raised from ₹200 crore to ₹500 crore in September 2022, then to ₹750 crore in August 2023. PK Healthcare contributed revenue of ₹15.96 crore and a loss after tax of ₹(44.20) million from its January 2024 acquisition date to March 31, 2024.
  4. Profit jump is tax-driven, not operational Major - Shalby elected the concessional tax regime under Section 115BAA in FY2025-26, lowering its normalised statutory tax rate to about 25% from around 35%. The election triggered a one-time tax credit of ₹34.02 crore recognised in the quarter ended March 31, 2026, partly offset by a ₹21.1 crore reassessment of subsidiary deferred-tax assets. Management stated in the Q4 FY26 earnings call that the consolidated PAT improvement to ₹34.7 crore from ₹1.9 crore is “by reason of the change in the tax regime”.
  5. Profits are not backed by operating cash flow Major - Cumulative operating cash flow of ₹294 crore was only 0.28 times cumulative EBITDA of ₹1,038 crore over the ten-year history. Consolidated CFO/PAT was -0.00x in FY2025-26 and -2.26x in FY2024-25. A ₹30.1 crore capital advance to the Santacruz Residential Association for a Mumbai hospital has remained outstanding, essentially unchanged, since March 2020.
  6. Promoter family consolidates board roles and pay Minor - Dr. Vikram Shah drew nil remuneration as Managing Director but was paid professional fees of ₹0.99 crore in FY2025-26 under consultancy agreements, with a February 2025 agreement stipulating payment of 70% of OPD income he generates for five years. His son Shanay Shah was appointed Whole-Time Director for five years effective August 12, 2026, with remuneration not exceeding ₹1.50 crore per annum. Public institutional shareholders voted 48.18% against Shanay Shah’s re-appointment to a place of profit at the September 2024 AGM.
  7. Disputed tax and arbitration load persists Minor - A GST demand of ₹6,20,80,588 plus an equivalent penalty was levied by the Joint Commissioner of CGST & Central Excise, Jabalpur, on 6 Feb 2025 for wrongly availed Input Tax Credit. An income-tax demand of ₹4,14,18,740 for AY 2015-16 was confirmed on 09.10.2023, with the company stating it will appeal before ITAT. The two doctor arbitrations were disposed of on 26 Jun 2026 pursuant to joint withdrawal or settlement, with impact stated as nil.
  8. Audit opinions carry key exceptions Clean - The statutory auditors issued unqualified opinions on standalone and consolidated financial statements for FY2019-20 through FY2025-26. The FY2025-26 CARO report notes that the audit trail feature is not enabled at the database level. The standalone auditor's report for FY2025-26 identifies multiple Key Audit Matters, including evaluation of uncertain legal and tax positions, allowance for expected credit loss, impairment assessment of investments in subsidiaries, and revenue recognition.
  9. Same statutory auditor since FY2018, no resignations Clean - T. R. Chadha & Co., LLP has been the statutory auditor since appointment at the 14th AGM on September 17, 2018, and was re-appointed for a second term of five years from August 2023. Total fees paid to statutory auditors by the company were ₹0.34 crore in FY2025-26, while subsidiary audit fees rose to ₹0.47 crore. The audit partner changed from Brijesh Thakkar to Arvind Modi for FY2024-25 and FY2025-26.

What to watch

Bottom line: This is a disclosed and audited record with a profitable standalone hospital business, but the audit trail feature is not enabled at the database level and the same statutory auditor has served since FY2018. The character of the risk is structural: a sprawling subsidiary network that absorbs standalone profit, a debt position that has risen while management called it comfortable, and profit growth that rests on a tax-regime change rather than operating cash flow. Watch the ICRA outlook, the PK Healthcare NCLT petition, and whether the Mumbai hospital advance ever converts into a functioning asset.